Ceribell Status Epilepticus Monitor

The Ceribell Status Epilepticus Monitor is a software medical device that analyzes EEG data from a proprietary 8-channel headband to automatically detect electrographic status epilepticus (ESE) in adult patients in acute care settings. Its methodology relies on an algorithm applying ACNS Guideline 14 criteria for ESE, demonstrating high sensitivity and specificity in clinical validation, aiming to expedite ESE diagnosis and treatment.

The Ceribell Status Epilepticus Monitor is a software medical device designed to aid clinicians in diagnosing electrographic status epilepticus (ESE) in adult patients (≥18 years) at risk for seizures within acute-care environments. It functions by analyzing electroencephalogram (EEG) waveforms captured exclusively using the Ceribell Pocket EEG Device and its 10-electrode Instant EEG Headband, which provides an 8-channel bipolar montage. The software's algorithm identifies EEG patterns consistent with ESE, as defined by the American Clinical Neurophysiology Society’s Guideline 14 (electrographic seizures lasting ≥ 10 continuous minutes or ≥ 20% of any 60-minute recording period). The binary output (ESE detected/not detected) is intended as an adjunctive diagnostic tool, to be integrated with other clinical findings, and does not replace comprehensive EEG review by a neurologist for other conditions. The device's performance was evaluated in a retrospective clinical validation study involving 350 adult subjects, comparing its algorithm's findings against a ground truth established by expert neurologists. This study demonstrated high diagnostic accuracy, with the software achieving 100% sensitivity in identifying the 10 ESE-positive cases (no false negatives) and 94% specificity in identifying ESE-negative cases (21 false positives out of 330). Notably, 19 of the 21 false-positive detections were associated with other seizure or epileptiform activity, indicating potential clinical relevance. The device, supported by successful bench-top verification, aims to accelerate ESE diagnosis and thereby reduce delays in initiating time-sensitive treatment in critical care.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. Given the 100% sensitivity was observed in a relatively small sample of 10 ESE-positive cases, how might the confidence intervals for sensitivity change with a larger, more diverse ESE-positive cohort, and what is the minimum clinically acceptable sensitivity?; The device uses a specific 10-electrode bipolar montage; how does its ESE detection performance compare to standard, full-montage EEG systems, particularly in detecting subtle or focal ESE manifestations that might be missed by a reduced montage?; Of the 21 false-positive ESE detections, 19 were noted to have other seizures or epileptiform activity. Could the device be further refined or provide nuanced output to differentiate these clinically significant non-ESE events from true negatives or less critical EEG patterns?; The device is intended for acute-care environments and not Epilepsy Monitoring Units. What specific device characteristics or performance limitations underpin this restriction, and could future iterations expand its utility to EMUs?; How does the algorithm account for potential EEG artifacts common in acute care settings (e.g., from patient movement, electrical interference), and what is its robustness in maintaining diagnostic accuracy under such conditions compared to neurologist interpretation?